Core Viewpoint - The company announced promising clinical results for HTD1801, indicating its potential to improve kidney function in patients with mild renal impairment, showcasing significant health benefits for chronic kidney disease (CKD) patients [1][2]. Group 1: Clinical Data and Results - HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) designed to address cardiorenal metabolic system diseases (CKM) by activating AMPK and inhibiting NLRP3 [1]. - The data presented is based on a pooled analysis from two Phase III randomized, double-blind, placebo-controlled studies (SYMPHONY 1 & 2; N=956) conducted in patients with type 2 diabetes (T2DM) [1]. - In patients with mild renal impairment (baseline eGFR: 60-90 ml/min/1.73m), HTD1801 significantly improved eGFR compared to placebo, with a positive slope observed during treatment [2]. - In patients with hyperfiltration (baseline eGFR ≥120 ml/min/1.73m), HTD1801 reduced eGFR compared to placebo, suggesting a potential to restore kidney function to normal levels [2]. Group 2: Safety Profile - HTD1801 did not show adverse effects on blood pressure, blood sodium, or blood potassium levels during the treatment period [2].
2025 ASN最新突破性专场|君圣泰医药-B(02511.HK)展示HTD1801肾脏获益数据